GBS Inc. Reports Fourth Quarter and Full Year 2021 Preliminary Financial Results and Recent Business Highlights
11 août 2021 16h05 HE
|
GBS Inc.
- Awarded $4.7 Million Government Grant Funding to support the building of a high-tech manufacturing facility - - Signs Strategic Partnerships with Johns Hopkins University, Wyss Institute from...
GBS Inc. to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on August 11
29 juil. 2021 08h30 HE
|
GBS Inc.
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...
GBS Inc. Engages L.E.K. Consulting Hong Kong Pty Limited to Identify Potential Sublicensees in China for its Saliva-Glucose Diabetes Test
26 juil. 2021 08h00 HE
|
GBS Inc.
NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...
GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology
08 juil. 2021 09h21 HE
|
GBS Inc.
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...
Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick’ Alternative in Global Glucose Monitoring Survey
08 juin 2021 08h10 HE
|
GBS Inc.
NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...
GBS Inc. Reports First Quarter 2021 Financial Results and Recent Business Highlights
14 mai 2021 08h30 HE
|
GBS Inc.
- Anticipate Emergency Use Submission for SARS-CoV-2Antibody Biosensor Test in the Second Half of 2021- - $14 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2021,...
GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test
15 avr. 2021 11h29 HE
|
GBS Inc.
NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- GBS, Inc. (NasdaqGS: GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for...
GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests
18 févr. 2021 08h53 HE
|
GBS Inc.
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary...
GBS Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
16 févr. 2021 08h00 HE
|
GBS Inc.
- December 2020 Initial Public Offering generated $21.6m in gross proceeds andlisting on the NASDAQ Stock Market -Executes Partnerships, Research Collaboration and Commercial Agreements-- John...
GBS, Inc. Announces Closing of Upsized $21.6 Million Initial Public Offering
28 déc. 2020 17h13 HE
|
GBS Inc.
NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their...